Therefore, the objective of this systematic review was to critically evaluate the sustained efficacy and safety of GLP-1 receptor agonists in the long-term management of obesity, focusing on randomized controlled trials that assess weight maintenance, cardiometabolic outcomes, and adverse event profiles. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.